News

Mallinckrodt’s INOmax Approved in Australia for Adults with Perioperative PH and Heart Surgery

The health regulatory agency for Australia has approved Mallinckrodt Pharmaceuticals‘ INOmax (nitric oxide) gas for inhalation as a treatment for adult patients with perioperative pulmonary hypertension (PH) in combination with cardiovascular (heart) surgery. INOmax is a vasodilator inhalation device that works by widening and relaxing blood vessels…

FDA Agrees to Change Study of Bellerophon’s INOpulse for PH-ILD Patients

The U.S. Food and Drug Administration (FDA) has agreed to change the ongoing Phase 2b study  evaluating INOpulse in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) into a Phase 2/3 clinical trial, the therapy’s manufacturer, Bellerophon Therapeutics, announced. With this decision the agency also agreed to change the…

Certain Patients with Sarcoidosis-associated PH May Benefit from PH-specific Treatment, Real-world Study Suggests

Patients with sarcoidosis-associated pulmonary hypertension (SAPH) can improve their levels of a key biomarker after receiving specific treatment for PH, which suggests that PH-specific treatment may benefit this patient population, according to a real-world study. The study, “Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary…

Sandoz Launches Treprostinil Injection, First Remodulin Generic, in the US for PAH Treatment

The pharmaceutical company Sandoz announced the commercialization of an injectable form of the vasodilating therapy treprostinil for treating exercise-related symptoms affecting individuals with pulmonary arterial hypertension (PAH). This treprostinil injection is the first generic substitute (the non-branded version of a developed therapy) of Remodulin, developed and sold…